Company

OMEICOS Therapeutics GmbH

OMEICOS Therapeutics develops therapies for cardiovascular, inflammatory and mitochondrial diseases, based in Berlin, Germany.

About

Founded in 2013 in Berlin, Germany, OMEICOS Therapeutics GmbH develops therapies for cardiovascular, inflammatory and mitochondrial diseases. Its lead product, OMT-28, has been tested in a Phase 2 study in patients with atrial fibrillation. CEO Robert Fischer leads the firm, which has completed 9 deals and secured a total of EUR 17.000 mn across funding rounds, including a GRANT of EUR 2.500 mn from the Federal Ministry of Education and Research. The listed stage is Series C.

5Funding rounds

5Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in